Team:Washington/Celiacs/Background

From 2011.igem.org

Revision as of 19:18, 10 September 2011

Introduction Celiac sprue is a highly prevalent disease in which dietary proteins found in wheat, barley, and rye products known as ‘glutens’ evoke an immune response in the small intestine of genetically predisposed individuals. The resulting inflammation can lead to the degradation of the villi of the small intestine, impeding the absorption of nutrients. Symptoms can appear in early childhood or later in life, and range widely in severity, from diarrhea, fatigue and weight loss to abdominal distension, anemia, and neurological symptoms. There are currently no effective therapies for this lifelong disease except the total elimination of glutens from the diet. Although celiac sprue remains largely underdiagnosed, its’ prevalence in the US and Europe is estimated at 0.5-1.0% of the population (1, 2). Proline (P)- and glutamine (Q)-rich components of gluten known as ‘gliadins’ appear to be responsible for the bulk of the immune response in most patients (1). Their high PQ content protects gliadin oligopeptides from degradation by gastrointenstinal endoproteases, but also presents a target for drug design. Any peptidase capable of cleaving at or near the P-Q bond while remaining active at the temperature and harsh pH of the stomach would have pharmacological potential as a therapy for celiac sprue. One candidate enzyme, currently in clinical trials, utilizes a prolyl endopeptidase (PEP) from Sphingomonas capsulata (SC) to hydrolyze gliadins. This enzyme was a logical drug candidate as it has a native specificity for the proline rich gliadin peptides. Unfortunately, the enzyme’s optimal activity is at pH 7, and engineering attempts to enhance its activity at relevant gastric pH levels has not yet met with significant success (3). It is therefore pertinent to identify new candidate enzymes that have both the specificity for the PQ gliadin structural motif as well as optimal activity at gastric pH levels. In this study we describe an alternative approach to identifying and engineering an enzyme therapeutic for celiac sprue disease. Rather than focusing primarily on substrate specificity, we identified an enzyme already capable of catalyzing peptide hydrolysis at gastric pH levels, regardless of peptide substrate specificity. Upon identification of such an enzyme we used computational tools to reengineer the substrate specificity for enhanced activity towards immunogenic gliadin peptides with the common PQ structural motif.

Results and Discussion

Enzyme Identification

	When searching for a protease with optimal activity at gastric pH levels that could be produced in a recombinant host, we identified an enzyme known as Kumamolisin-As. Kumamolisin-As was isolated from the thermoacidophilic bacterium Alicyclobacillus sendaiensis strain NTAP-1, has been shown to be produced in a recombinant host, and exhibits significant enzymatic activity from pH 2.5 and above. Its maximal activity is at pH ~4.0. Kumamolisin-As is a member of the sedolisin family of serine-carboxyl peptidases, and utilizes the key catalytic triad Ser278-Glu78-Asp82 to hydrolyze its substrate. While the native substrate for this enzyme is unknown, it has been previously shown to degrade collagen under acidic conditions (4). In addition, this enzyme has been shown to be thermostable, with an ideal temperature at 600C, but still showing significant activity at 370C.  

Specificities studies have also been done, and the enzyme is most stringent at the P1 and P2 subsites, the ideal amino acids being R and P, respectively. The combination of Kumamolisin-As having the desired enzymatic activity under gastric pH levels, and the P2 subsite already having the specificity for the proline from the desired PQ motif makes it a highly attractive candidate for further engineering. In addition, several crystal structures of this enzyme have been solved, allowing for the use of computational design techniques.